Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. RetinalGenix Technologies's
Operating Income
for the
three
months ended in Mar. 2026 was $-0.59 Mil. RetinalGenix Technologies's Interest Expense for the
three
months ended in Mar. 2026 was $-0.00 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for RetinalGenix Technologies's Interest Coverage or its related term are showing as below:
RTGN's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 16.545 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
RetinalGenix Technologies Interest Coverage Related Terms
RetinalGenix Technologies Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
RTGN vs SNWV, NNOX, LNSR: Interest Coverage Comparison
For the Medical Devices subindustry, RetinalGenix Technologies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RetinalGenix Technologies Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RetinalGenix Technologies's Interest Coverage distribution charts can be found below:
* The bar in red indicates where RetinalGenix Technologies's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
RetinalGenix Technologies did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
RetinalGenix Technologies (RTGN) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on RetinalGenix Technologies and its competitors.
Is RetinalGenix Technologies' Interest Coverage too high?
RetinalGenix Technologies' current Interest Coverage is 0 (At Loss). Overall, RetinalGenix Technologies has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does RetinalGenix Technologies' Interest Coverage compare to SNWV and NNOX?
RetinalGenix Technologies' Interest Coverage of 0 (At Loss) can be compared against companies in the Medical Devices & Instruments industry. The industry median Interest Coverage is 16.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.55, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on RetinalGenix Technologies and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RetinalGenix Technologies's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RetinalGenix Technologies stock overvalued right now?
RetinalGenix Technologies (RTGN) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). RetinalGenix Technologies' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For RetinalGenix Technologies (RTGN), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: Retinal Imaging Screening Device a portable, retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available.
30GF Score
Get the complete analysis for RTGN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RTGN has been successfully added to your 
